Sirnaomics this week announced that it has received a Small Business Innovation Research grant from the National Cancer Institute to develop novel siRNA-based therapeutics for lung cancer.
According to the NIH, the six-month grant began on June 1 and is worth $250,000. The company will use the funds to develop multi-targeted siRNA drugs for non-small cell lung cancer.
"We will test this drug candidate in A549 and H460 xenograft tumor models for its antitumor efficacy and safety profiles," the company said in the grant's abstract. "We will also use HKP and PTL nanoparticle[s] to further enhance the siRNA cocktail therapeutics, targeting EGFR, VEGF, Cox-2, or PDGF oncogenic genes."
Sirnaomics added that it will also examine the efficacy of its therapies in combination with existing small-molecule and antibody drugs in animal models.